Lineage Cell Therapeutics, Inc. fell 10.8% on Thursday, November 12, 2026, on 1,376,100 shares. Headlines around the move:
Lineage Cell Therapeutics, Inc. (LCTX:NYSEMKT) closed at $0.915 on November 13, 2026, down 7.64% on the day. The stock trades 54.0% below its 52-week high of $1.99 and 3.9% above its 52-week low of $0.880. Over the past year, it lost 51.4%. Lineage Cell Therapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, LCTX closed higher on 107 days (42%). Its best day was February 3, 2026 (+14.29%) and its worst was November 12, 2026 (-10.81%). The stock moved 10% or more in a single session 3 times.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. BioTime's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.
Find more stocks like LCTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.